ADXN Addex Pharmaceuticals S.A.

Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders

Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders

Ad Hoc Announcement Pursuant to Art. 53 LR

Geneva, Switzerland – June 30, 2025 – (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced it has led a CHF 2 million investment in Stalicla, a clinical-stage company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders. Stalicla will use the financing to advance its portfolio of autism focused drug candidates, support the partnering of certain assets and its series C financing as well as general corporate activities. As part of the Addex-led financing, Addex CEO, Tim Dyer, has been appointed to Stalicla’s Board of Directors and nominated as Chairman.

“This strategic investment underscores Addex’s commitment to advancing innovative treatments for CNS disorders and builds on our 20% equity holding in Neurosterix. Stalicla has built a world leading precision medicine platform in neurodevelopmental disorders, backed by a strong portfolio of clinical-stage assets,” said Tim Dyer, CEO of Addex. “We look forward to providing our industry expertise to support the Stalica team as they bring forward these new treatment options for this underserved patient population.”

The investment in Stalicla reinforces Addex’s strategy to support the advancement of precision therapeutics in CNS disorders. Stalicla is preparing to launch Phase 2 trials for its lead autism candidate STP1 and a second asset, both targeting specific subpopulations within autism spectrum disorder (ASD). Stalicla is also advancing its STP7 program (mavoglurant), an mGluR5 NAM, for cocaine use disorders under a Collaborative Research and Development Agreement (CRADA) with the NIH’s National Institute on Drug Abuse (NIDA). This program is the most advanced treatment candidate in development for this indication.

“We are delighted to welcome Addex and its syndicate of investors to Stalicla. Addex brings a wealth of life science expertise and we look forward to working with them to build significant value for our shareholders,” said Lynn Durham, CEO of Stalicla. “Stalicla is poised to advance a number of assets into phase 2 clinical studies for subpopulations of patients with ASD and is committed to transforming the lives of these patients and their families.”

About Stalicla

, a Swiss clinical stage biopharmaceutical company, has raised over $50m to date in equity and more than $30m in non-dilutive funding to propel its mission to transform the landscape of neurodevelopmental disorder (NDD) treatments. The company has established a clinically validated neuro precision development platform that effectively identifies stratified patient subgroups, enabling the advancement of personalized treatment options. Currently, Stalicla is preparing to initiate Phase 2 trials for its leading NDD asset, STP1, along with a second asset, both targeting specific subpopulations within autism. Additionally, STP7 (mavoglurant) is progressing towards Phase 3 trials, with full funding provided by the US government.

About Addex Therapeutics

Addex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex’s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit

  

Contacts: 

Tim Dyer 

Chief Executive Officer 

Telephone: 5 

 
Mike Sinclair 

Partner, Halsin Partners 

+44 (0)7968 022075 

 

Addex Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.



EN
30/06/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Addex Pharmaceuticals S.A.

 PRESS RELEASE

Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision ...

Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced it has led a CHF 2 million investment in Stalicla, a clinical-stage company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders. Stalicla will use the financing to advance its portfolio of auti...

 PRESS RELEASE

Addex Shareholders Approve All Resolutions at Annual General Meeting

Addex Shareholders Approve All Resolutions at Annual General Meeting Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, June 25, 2025 - (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2025 Annual General Meeting (AGM). The votes represented 30.18% of the company's outstanding capital. Addex shareholders approved the 2024 annual report, the 2024 annual financial state...

 PRESS RELEASE

Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corp...

Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update Strong cash position of CHF2.8 million at end of Q1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM Substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for an exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerla...

 PRESS RELEASE

Addex Therapeutics to Release Q1 2025 Financial Results and Host Confe...

Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025 Geneva, Switzerland, June 18, 2025 - (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Q1 2025 Financial Results on June 19, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and me...

 PRESS RELEASE

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in...

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, June 6, 2025 - (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in multiple preclinical models of chronic cough compared to reference drugs...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch